Literature DB >> 2533582

Increase of plasma atrial natriuretic peptide levels after sublingual administration of nifedipine in essentially hypertensive patients.

A Rappelli1, P Dessì-Fulgheri, F Bandiera, G Di Noto.   

Abstract

To see whether the acute natriuretic effect of nifedipine is accompanied by changes in atrial natriuretic peptide levels, a group of eight hypertensive patients were studied. After at least a week of constant sodium intake, placebo or nifedipine (10 mg s.I.) were administered and blood pressure, heart rate, plasma renin activity, plasma aldosterone and atrial natriuretic peptide plasma levels, urinary sodium, urinary volume and creatinine clearance were monitored for 2 hours. While placebo did not induce changes in any of the above parameters, nifedipine administration was followed by a significant decrease in blood pressure and an increase in urinary sodium, urinary volume and creatinine clearance; these changes were accompanied by a significant rise in atrial natriuretic peptide levels from 19.4 +/- 2.8 pg/ml to a maximum of 23.9 +/- 2.5 pg/ml and 24.1 +/- 2.2 pg/ml (P less than 0.05) at 60 and 90 minutes, respectively. In conclusion, our data do not rule out the possibility that atrial natriuretic peptide participates in the nifedipine-induced increase in sodium and water excretion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533582     DOI: 10.1016/0167-5273(89)90089-2

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

1.  Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil.

Authors:  B Kokkas; P Kotridis; M Karamouzis; I Kanonidis; G Sakadamis; G Dadous; S Haritos; P Kyriakoui; P C Papadopoulos; V Mirtsou-Fidani; C L Papadopoulos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

2.  The dihydropyridine calcium channel blocker BAY t 7207 attenuates the exercise induced increase in plasma ANF and cyclic GMP in patients with mildly impaired left ventricular function.

Authors:  M Kentsch; W Otter; C Drummer; V Peinke; K Theisen; G Müller-Esch; R Gerzer
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 3.  Atrial natriuretic peptide contributes to the antihypertensive action of many drugs.

Authors:  C L Papadopoulos; B A Kokkas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.